

Olumiant leads the alopecia Jak pack



Madeleine Armstrong

Lilly and Incyte today claimed the first pivotal win for a Jak inhibitor in alopecia – but it might not be the last. The groups’ Olumiant succeeded in Brave-AA2, but Pfizer is not too far behind with its Jak3/TEC inhibitor ritlecitinib, whose phase II/III study is also set to report in 2021. Lilly is not disclosing data from Brave-AA2, only saying that both doses tested, 2mg and 4mg once daily, met the primary efficacy endpoint, the percentage of patients achieving a severity of alopecia tool (Salt) 20 score at 36 weeks. Ritlecitinib’s Allegro-2b/3 trial also evaluates Salt 20, at week 24, so if it hits it will be interesting to see how the projects stack up. Safety will also be under scrutiny given [Jak inhibitors’ track record](#). Lilly said that in Brave-AA2 Olumiant’s safety profile was consistent with experience in rheumatoid arthritis, for which it is FDA approved, and atopic dermatitis, for which it has EMA approval. Still, Olumiant’s [US label](#) has a black box warning for serious infections, malignancies and thromboses, which might hurt its chances in a disease like alopecia. The sellside forecasts Olumiant sales of \$1.2bn in 2026, according to *EvaluatePharma* consensus, but none of this is expected to come in alopecia.

Jak inhibitors in active clinical development for alopecia

Project	Company	Pharma class	Trial ID	Data due
Phase III				
Olumiant	Lilly	Jak 1 & 2 inhibitor	BRAVE-AA2	Toplined Mar 2021, 2mg & 4mg doses met primary endpoint
			BRAVE-AA1	Completed Feb 2021
Ritlecitinib (PF-06651600)	Pfizer	Jak 3/TEC inhibitor	Allegro-2b/3	Completed Dec 2020
CTP-543	Concert	Jak 1 & 2 inhibitor	Thrive-AA1	Completes Feb 2022
			Thrive-AA2	Due to start H1 2021
Phase II				
Jaktinib (oral)	Suzhou Zelgen Biopharmaceuticals	Jak 1-3 inhibitor	NCT04034134 (severe)	Completed Dec 2020
Jaktinib (topical)	Suzhou Zelgen Biopharmaceuticals	Jak 1-3 inhibitor	NCT04445363 (mild to moderate)	Completed Dec 2020

Source: *EvaluatePharma* & *clinicaltrials.gov*.

More from Evaluate Vantage

Evaluate HQ
[44-\(0\)20-7377-0800](tel:44-020-7377-0800)

Evaluate Americas
[+1-617-573-9450](tel:+1-617-573-9450)

Evaluate APAC
[+81-\(0\)80-1164-4754](tel:+81-080-1164-4754)

